Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Leukemia, Myeloid, Acute 45Breast Neoplasms 20Myelodysplastic Syndromes 19Prostatic Neoplasms 12Neoplasms 12Leukemia, Myelomonocytic, Chronic 12Carcinoma, Hepatocellular 10Stomach Neoplasms 9Recurrence 9Carcinoma, Non-Small-Cell Lung 8Neoplasm Metastasis 7Esophageal Neoplasms 7Uterine Cervical Neoplasms 6Sarcoma 6Ovarian Neoplasms 6Multiple Myeloma 6Lung Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 5Melanoma 5Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Myelodysplastic-Myeloproliferative Diseases 4Leukemia, Biphenotypic, Acute 4Cholangiocarcinoma 4Thrombocythemia, Essential 3

Interventions

fluorodopa F 18 3pasireotide 1dapagliflozin 1amino-acid, glucose, and electrolyte solution 1Surveys and Questionnaires 1Sugars 1Solutions 1Saline Solution 1Pioglitazone 1Metformin 1Insulin 1Injections 1Diazoxide 1Amino Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hyperinsulinism × Injections × Clear all
NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Montefiore Medical Center

Phase 2 Withdrawn
Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡